drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR T-cell therapy)
drug_description
An autologous, fully human anti-BCMA CAR T-cell therapy (CT103A) for relapsed/refractory multiple myeloma. Patient T cells are engineered to express a CAR targeting BCMA, leading to T-cell activation, expansion, cytokine release, and cytotoxic killing of BCMA-positive plasma cells.
nci_thesaurus_concept_id
C185123
nci_thesaurus_preferred_term
Equecabtagene Autoleucel
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that have been transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) with a fully human single chain variable fragment (scFv) targeting the human tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17), with potential immunostimulating and antineoplastic activities. Upon administration, equecabtagene autoleucel specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells, and plays a key role in plasma cell proliferation and survival.
drug_mesh_term
CT103A chimeric antigen receptor
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered via lentiviral transduction to express a fully human anti-BCMA chimeric antigen receptor. Upon binding BCMA on malignant plasma cells, CAR signaling activates the T cells, inducing proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of BCMA-positive cells.
drug_name
Equecabtagene autoleucel
nct_id_drug_ref
NCT06369935